These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32749910)

  • 1. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
    Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
    Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
    Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Zeineddine M; Al-Roughani R; Farouk Ahmed S; Khoury S; El-Ayoubi N; Al-Mahdawi A; Al-Khabouri J; Al-Asmi A; Chentouf A; Inshasi J; Gouider R; Mrabet S; Shalaby N; Massouh J; Mohamed Ramzy Hasan Mohamed F; Al-Hajje A; Salameh P; Dimassi H; Boumediene F; Yamout B
    Mult Scler; 2024 Jul; 30(8):1026-1035. PubMed ID: 39054846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
    J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
    Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
    Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
    Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
    Brown JD; Muston BT; Massey J
    Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of natalizumab extended interval dosing.
    Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
    Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.